Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on July 18, 2012. The registrant is a Delaware corporation headquartered in Solana Beach, California, focused on the development of drug candidates, specifically Impracor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation agreements rather than financial performance.
Material Changes
The primary material change reported is the entry into definitive agreements regarding executive compensation:
- CEO Grant: On July 18, 2012, the Board granted Mark L. Baum (CEO) 800,000 Restricted Stock Units (RSUs) outside the 2007 Incentive Stock and Awards Plan.
- Consultant Grant: On the same date, the Board granted Dr. Robert J. Kammer (Consultant) 200,000 RSUs outside the 2007 Incentive Stock and Awards Plan.
Guidance, Outlook, and Risks
The RSU grants are tied to specific performance milestones and contingencies rather than standard time-based vesting:
- CEO Vesting Criteria: 200,000 RSUs vest upon each of the following: (i) completion of financing raising at least $5,000,000; (ii) meeting primary endpoints of Phase III clinical studies for Impracor; (iii) submission of a New Drug Application (NDA) for Impracor; and (iv) entering a definitive license or collaboration agreement for Impracor expected to generate cash flow.
- Consultant Vesting Criteria: All 200,000 RSUs vest upon meeting the primary endpoints of Phase III clinical studies for Impracor.
- Change in Control: All RSUs granted to both individuals vest in full upon a change in control of the Company.
Investor Verification Checklist
- Verify the current status of the Phase III clinical studies for Impracor to assess vesting probability.
- Confirm whether the Company has secured the $5,000,000 financing required for partial CEO vesting.
- Review the Company's 2007 Incentive Stock and Awards Plan to understand the impact of these "stand-alone" grants on total equity dilution.
- Monitor for any announcements regarding a New Drug Application (NDA) submission or collaboration agreements for Impracor.